Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating diabetes using oral agents.

Tariq Malik1, Dace L Trence

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.

Primary Care
|December 25, 2003
PubMed
Summary

New oral diabetes medications offer flexible treatment for type 2 diabetes mellitus (T2DM). While metformin is a preferred first-line therapy, combination treatments and novel agents are needed to overcome limitations and address underlying disease mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Procedural Interventions for the Treatment of Cancer Pain.

International anesthesiology clinics·2025
Same author

Periodontitis and quality of life in adults with cystic fibrosis - A pilot cross-sectional study.

Community dental health·2025
Same author

Indirect and Direct Lumbar Spine Decompression: Indications, Patient Selection, Efficacy, and Outcomes.

International anesthesiology clinics·2025
Same author

A comparison of MRI and intraoperative measurements to determine interspinous spacer device size.

Pain practice : the official journal of World Institute of Pain·2025
Same author

The association between cystic fibrosis-related diabetes and periodontitis in adults: A pilot cross-sectional study.

PloS one·2024
Same author

Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review.

Mediastinum (Hong Kong, China)·2024

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Diabetes Research

Background:

  • Sulfonylureas were early oral agents for type 2 diabetes mellitus (T2DM).
  • Metformin is the preferred monotherapy for overweight/obese T2DM patients.
  • Combination therapies improve glycemic control but have limitations.

Purpose of the Study:

  • To review current oral glycemic control agents for T2DM.
  • To highlight the need for novel therapeutic strategies.
  • To explore agents addressing insulin resistance, production, and diabetes prevention.

Main Methods:

  • Literature review of existing evidence on T2DM pharmacotherapy.
  • Analysis of current treatment guidelines and limitations.
  • Discussion of unmet needs in T2DM management.

Main Results:

  • Metformin monotherapy is recommended for most overweight or obese T2DM patients.
  • Combination therapy enhances glycemic control but faces challenges.
  • Secondary oral agent failure and side effects limit long-term efficacy.

Conclusions:

  • Current oral agents for T2DM have limitations, including side effects and secondary failure.
  • There is a significant need for new medications.
  • Future agents should target insulin resistance, insulin production, and diabetes prevention in at-risk populations.

Related Experiment Videos